Fmoc-(2S,4R)-(4-OCO-NH-CH2-CH2-NH-Boc)-Pro-OMe | 187223-14-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-(2S,4R)-(4-OCO-NH-CH2-CH2-NH-Boc)-Pro-OMe
• 英文别名: 1-O-(9H-fluoren-9-ylmethyl) 2-O-methyl (2S,4R)-4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylcarbamoyloxy]pyrrolidine-1,2-dicarboxylate
• CAS: 187223-14-9
• 化学式: C₂₉H₃₅N₃O₈
• 分子量: 553.612
• InChiKey: PTEYJHPEZRFGFI-KOSHJBKYSA-N

物化性质

• 沸点：
  707.0±60.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  40
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Fmoc-(2S,4R)-(4-OCO-NH-CH2-CH2-NH-Boc)-Pro-OMe 在 sodium hydroxide 、 三氟乙酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 19.0h， 生成 Fmoc-(2S,4R)-(4-OCO-NH-CH2-CH2-NH2)-Pro-OH
  参考文献：
  名称：

  A Novel Somatostatin Mimic with Broad Somatotropin Release Inhibitory Factor Receptor Binding and Superior Therapeutic Potential

  摘要：

  A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery of SOM230 (25), a novel, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1-sst5). SOM230 has potent, long-lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase I clinical trials.

  DOI：

  10.1021/jm021093t
• 作为产物：
  描述：

  N-Fmoc-反式-4-羟基-L-脯氨酸甲酯 在 4-二甲氨基吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 Fmoc-(2S,4R)-(4-OCO-NH-CH2-CH2-NH-Boc)-Pro-OMe
  参考文献：
  名称：

  A Novel Somatostatin Mimic with Broad Somatotropin Release Inhibitory Factor Receptor Binding and Superior Therapeutic Potential

  摘要：

  A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery of SOM230 (25), a novel, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1-sst5). SOM230 has potent, long-lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase I clinical trials.

  DOI：

  10.1021/jm021093t

文献信息

• [EN] NOVEL PROCESS FOR THE PREPARATION OF PASIREOTIDE<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE PASIRÉOTIDE
  申请人：BIOPHORE INDIA PHARMACEUTICALS PVT LTD

  公开号：WO2016207912A1

  公开（公告）日：2016-12-29

  The present invention relates to a novel process for the preparation of Pasireotide of formula 11 [Cyclo [Phe-4-(OCO-NH-CH2-CH2-NH2)) Pro}-Phg-DTrp-Lys-Tyr(Bzl)]]. The invention also relates to a novel intermediate compound of formula 8 and process thereof which is used for preparation of compound of formula 11.

  本发明涉及一种用于制备化学式11的帕西瑞肽的新型工艺。该发明还涉及一种化学式8的新型中间化合物及其制备工艺，该中间化合物用于制备化合物11。
• A Novel Somatostatin Mimic with Broad Somatotropin Release Inhibitory Factor Receptor Binding and Superior Therapeutic Potential
  作者：Ian Lewis、Wilfried Bauer、Rainer Albert、Nagarajan Chandramouli、Janos Pless、Gisbert Weckbecker、Christian Bruns

  DOI：10.1021/jm021093t

  日期：2003.6.1

  A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery of SOM230 (25), a novel, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1-sst5). SOM230 has potent, long-lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase I clinical trials.